

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2005 HIGHEST RN 862883-42-9  
 DICTIONARY FILE UPDATES: 11 SEP 2005 HIGHEST RN 862883-42-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-743581.str



chain nodes :

1 19 20 21 22 23 24 25 27 28 29 30

ring nodes :

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-21 11-27 17-22 19-20 19-22 19-23 20-21 20-24 21-25 27-28 28-29 28-30

ring bonds :

2-5 2-6 3-4 3-5 3-6 4-7 4-8 5-9 7-10 8-11 8-12 9-11 10-13 10-14 12-15  
 13-16 14-17 15-16 16-18 17-18

exact/norm bonds :

1-21 11-27 17-22 19-22 19-23 20-24 21-25 27-28 28-29 28-30

exact bonds :

2-5 2-6 3-4 3-5 3-6 4-7 4-8 5-9 7-10 8-11 8-12 9-11 10-13 10-14 12-15  
 13-16 14-17 15-16 16-18 17-18 19-20 20-21

isolated ring systems :

containing 2 :

Match level :


1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 27:CLASS 28:CLASS  
29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 18:33:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 965 TO ITERATE

100.0% PROCESSED 965 ITERATIONS

SEARCH TIME: 00.00.01

45 ANSWERS

L2 45 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 18:34:01 ON 12 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Sep 2005 VOL 143 ISS 12  
FILE LAST UPDATED: 11 Sep 2005 (20050911/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 4 L2

=> d ibib abs hitstr tot


LJ ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2001:581881 CAPLUS  
DOCUMENT NUMBER: 135:152986  
TITLE: Preparation of C7 carbonate substituted taxanes for  
use as antitumor agents  
INVENTOR(S): Holton, Robert A.  
PATENT ASSIGNEE(S): Florida State University Research Foundation, Inc.,  
USA  
SOURCE: PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
PATENT ACC. NUM. COUNT: 9  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057030	A1	20010809	WO 2001-US3554	20010202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, SD, SE, SG, SI, SK, SL, TJ, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, CY, RW: GH, GM, KE, LS, LM, MW, NZ, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, FR, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, CY, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368540	AA	20010809	CA 2001-2368540	20010202
AU 2001034793	A5	20010814	AU 2001-34793	20010202
AU 776122	B2	20040826		
BR 2001004351	A	20020102	BR 2001-4351	20010202
EP 1165552	A1	20010102	EP 2001-906952	20010202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002052403	A1	20020502	US 2001-776122	20010202
US 6638973	B2	20031028		
US 2002065304	A1	20020530	US 2001-776137	20010202
US 6780879	B2	20040824		
TR 200102857	T1	20040624	TR 2001-02857	20010202
JP 200352170	A1	20030912	JP 2003-52170	20010202
NZ 514380	A	20050324	NZ 2001-514380	20010202
EP 1285919	A1	20030226	EP 2001-187727	20010806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2001004755	A	20011129	NO 2001-4755	20011001
BG 105966	A	20020731	BG 2001-105966	20011001
US 2001080851	A	20021201	ZA 2001-8051	20011001
US 2004097579	A1	20040529	US 2001-90649	20031007
US 2004138267	A1	20040715	US 2003-743581	20031222
US 2005165051	A1	20050528	US 2005-82380	20050317
PRIORITY CLAIM. INFO.:			US 2000-177671P	P 20000202

PRIORITY APPLN. INFO.:

L3	ANSWER 1 OF 4	CAPLUS	COPYRIGHT 2005	ACS on STN	(Continued)
				US 2000-179672P	P 20000202
				US 2000-179684P	P 20000202
				US 2000-179782P	P 20000202
				US 2000-179793P	P 20000202
				US 2000-179794P	P 20000202
				US 2001-776137	A1 20010202
				US 2001-776426	A3 20010202
				WO 2001-US3554	W 20010202
				US 2003-743581	A1 20031222

OTHER SOURCE(S) :                    HARPAT 135:152986  
GI



AB Taxanes I (R = acyloxy; R1 = carbonate; R2 = keto, hydroxy, acyloxy; R3 = hydroxy; R4 = hydrido, hydroxy; X = substituted or unsubstituted alkyl, alkenyl, alkynyl, Ph, heterocyclo; X1 = COX2, CO2X2, CONHX2; X2 = hydrocarbyl, substituted heterocyclyl, heterocyclo; Ac = acetyl) having a

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
carbonate substituent at C(7) were prep'd. and tested as antitumor agents.  
II was prep'd. and had in vitro cytotoxicity of ID50 of < 1 nM against  
HCT116 cells. Pharmaceutical compns. contg. I are described.

IT 352427-29-3P 352698-10-1P 352698-19-2P  
352698-20-5P 352698-21-6P 352698-22-7P  
352698-23-8P 352698-24-9P 352698-25-0P  
352698-26-1P 352698-28-3P 352698-29-4P  
352698-30-7P 352698-31-0P 352698-32-9P  
352698-33-0P 352698-34-1P 352698-36-3P  
352698-39-6P 352698-41-0P 352698-43-2P  
352698-45-4P 352698-46-5P 352698-48-7P  
352698-49-0P 352698-50-1P 352698-51-2P  
352698-53-4P 352698-54-5P 352698-56-6P  
352698-56-7P 352698-57-8P 352698-58-9P  
352698-59-0P 352698-60-3P 352698-61-4P  
352698-62-5P 352698-63-6P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of C7 carbonate substituted taxanes for use as antitumor agents)

RN 352427-29-3 CAPLUS  
 CN 2-Furanpropenoic acid,  $\beta$ -{[(1,1-dimethylpropoxy)carbonyl]amino}-  
 $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-  
 (benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-

4a,8,13,13-tetramethyl-5-oxo-4-[[{(phenylmethoxy)carbonyl}oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI)  
(CA INDEX NAME)


**Absolute stereochemistry.**



RN 352698-18-1 CAPIUS  
CN 2-Thiophenepropionic acid,  $\alpha$ -hydroxy- $\beta$ -[[[1-methylethoxy]carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetoxyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecachydro-6,11-dihydroxy-4-[[[methoxyethoxycarbonyl]oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclohexa[3,4]hept[1,2-b]oxet-9-yl ester. (aR,8R)-


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
(9CI) (CA INDEX NAME)

**Absolute stereochemistry.**



RN 352698-19-2 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(1-methylethoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetoxyloxy)-12-(benzyloxyloxy)-4-[(ethoxyxycarbonyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,RR)-(9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 352698-20-5 CAPLUS  
 CN 2-Thiophenepropionic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[ethoxycarbonyl(oxo)yl]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alpha,R)- (9CI) [CA]


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 352698-21-6 CAPLUS  
 CN 2-Thiophenepropanoic acid, β-[(benzoylamino)-α-hydroxy-4-((ethoxycarbonyl)oxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-22-7 CAPLUS  
 CN 2-Thiophenepropanoic acid, β-[(2-furanylcarbonyl)amino]-α-hydroxy-4-((ethoxycarbonyl)oxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Thiophenepropanoic acid, α-hydroxy-β-[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-25-0 CAPLUS  
 CN 2-Thiophenepropanoic acid, β-[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-4-((ethoxycarbonyl)oxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 [(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 352698-23-8 CAPLUS  
 CN 2-Thiophenepropanoic acid, β-[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-4-((ethoxycarbonyl)oxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-24-9 CAPLUS


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 352698-26-1 CAPLUS  
 CN 2-Thiophenepropanoic acid, β-[(2-furanylcarbonyl)amino]-α-hydroxy-4-((ethoxycarbonyl)oxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-28-3 CAPLUS  
 CN 2-Thiophenepropanoic acid, α-hydroxy-β-[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 RN 352698-29-4 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-30-7 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\beta$ -(benzoylamino)- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 352698-31-8 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-thienylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-32-9 CAPLUS  
 CN 3-Puranopropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 RN 352698-33-0 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-thienylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 352698-33-0 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-thienylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-34-1 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 RN 352698-36-3 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 352698-36-3 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-39-6 CAPLUS  
 CN 2-Puranopropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 352698-43-2 CAPLUS  
 CN 3-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-41-0 CAPLUS  
 CN 3-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 352698-46-5 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-48-7 CAPLUS  
 CN 2-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 352698-43-2 CAPLUS  
 CN 3-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-45-4 CAPLUS  
 CN 2-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 352698-49-8 CAPLUS  
 CN 2-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 352698-50-1 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BR)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 352698-51-2 CAPLUS

CN 2-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-

4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, (aR,BR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 352698-53-4 CAPLUS

CN 2-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 352698-55-6 CAPLUS

CN 2-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, (aR,BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 352698-56-7 CAPLUS


CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-

4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, (aR,BR) - (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, (aR,BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 352698-54-5 CAPLUS


CN 2-Puranpropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, (aR,BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 352698-57-8 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, (aR,BR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 352698-58-9 CAPLUS

CN 2-Puranpropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, (aR,BR) - (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 352698-59-0 CAPLUS  
 CN 3-Furanpropenoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 352698-60-3 CAPLUS  
 CN 3-Furanpropenoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 352698-62-5 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 352698-63-6 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BS)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 352698-61-4 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.  
 Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

LJ ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:581864 CAPLUS  
DOCUMENT NUMBER: 135:152983  
TITLE: Preparation and formulation of taxanes having  
improved solubility for pharmaceutical use as antitumor agents  
INVENTOR(S): Holton, Robert A.  
PATENT ASSIGNEE(S): Florida State University Research Foundation, Inc.,  
USA  
SOURCE: PCT Int. Appl., 319 pp.  
DOCUMENT TYPE: CODEN: PIXXD2  
LANGUAGE: Patent  
English  
FAMILY ACC. NUM. COUNT: 9  
PATENT INFORMATION:

ATTEST NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057013	Al	20010809	WG 2001-US3624	20010202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LG, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, FG, GZ, MO, NI, NO, NZ, PG, PH, PK, PR, PT, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, RW: DE, DK, ES, FI, FR, GB, GR, IL, IS, IT, LJ, MC, NL, PT, SE, CH, TR, BF, BI, CP, CG, CI, CM, GA, GM, GM, ML, MR, NE, SN, TD, TO				
CA 2367661	AA	20010809	CA 2001-2367661	20010202
AU 2001034810	A5	20010814	AU 2001-34810	20010202
US 2001051639	A1	20011213	US 2001-776492	20010202
US 6649632	B2	20031118		
BR 2001004358	A	20020102	BR 2001-4358	20010202
EP 1175414	A1	20020130	EP 2001-906972	20010202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LJ, LU, NL, SE, MC, PT, TR, IT, SI, LT, LV, FI, RO				
US 2001052403	A1	20020502	US 2001-776426	20010202
US 6638973	B2	20031028		
JP 2003521545	T2	20030715	JP 2001-556863	20010202
NZ 514073	A	20040227	NZ 2001-514073	20010202
CA 2354471	AA	20030131	CA 2001-2354471	20010731
ZA 2001006333	A	20020801	ZA 2001-6333	20010801
NO 2001004752	A	20011127	NO 2001-4752	20011001
ZA 2001008055	A	20031203	ZA 2001-8055	20011001
US 2003060638	B2	2002-11924	US 2002-71924	20020606
US 6750245	B2	20040615		
US 2004024051	A1	20040205	US 2003-609301	20030627
US 6872837	B2	20050329		
US 2004034230	A1	20040219	US 2003-618063	20030711
US 6906088	B2	20050614		
US 2004072872	A1	20040415	US 2003-676222	20031001
US 2004097579	A1	20040520	US 2003-680649	20031007
US 2004087547	A1	20040506	US 2003-720826	20031124
US 6814446	B2	20050301		
US 2004122055	A1	20040624	US 2003-720615	20031124
US 2004138267	A1	20040715	US 2003-743581	20031222

LJ	ANSWER 2 OF 4	CAPLWS	COPYRIGHT 2005	ACS	on STN	(Continued)
US	2005020635	A1	20050127	US	2004-867275	20040614
US	2005143446	A1	20050630	US	2005-63626	20050223
US	2005143447	A1	20050630	US	2005-68166	20050228
US	2005182098	A1	20050818	US	2005-67882	20050228
US	2005165051	A1	20050728	US	2005-82380	20050317
PRIORITY APPLN. INFO.:				US	2000-179669P	P 20000202

US 2000-179670P	P	20000202
US 2000-179671P	P	20000202
US 2000-179672P	P	20000202
US 2000-179674P	P	20000202
US 2000-179684P	P	20000202
US 2000-179782P	P	20000202
US 2000-179793P	P	20000202
US 2000-179794P	P	20000202
US 2001-275852	A1	20010202
US 2001-275912	A1	20010202
US 2001-276137	A1	20010202
US 2001-276274	A1	20010202
US 2001-276393	A1	20010202
US 2001-276626	A3	20010202
US 2001-276692	A1	20010202
US 2001-276694	A1	20010202
WO 2001-US3624	W	20010202
US 2002-71924	A1	20020206
US 2003-609301	A1	20030627
US 2003-618063	A1	20030711
US 2003-720826	A1	20031124
US 2003-743581	A1	20031222

OTHER SOURCE(S) : MARPAT 135:152983  
GI

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Taxanes, such as I [R7, R10 = H, acyl, carboxy, carbamoyl, etc.; X3 = alkyl, alkenyl, alkynyl, Ph, substituted Ph, heteroaryl; X5 = H, acyl, carboxyl, carboxamide, etc.] with improved solubility, were prepared for

Use as antitumor agents. Thus, taxotere analog II was prepared via esterification of baccatin III derivative III ( $R^7 = \text{COCH}_2\text{Me}$ ,  $R^{10} = \text{SiEt}_3$ ) with  $\beta$ -lactam IV followed by a deprotection step using HF. The prepared taxanes were tested for cytotoxic activity against HCT116 cells. Pharmaceutical formulations of the prepared taxanes were also presented.


IT	Formulations of the prepared taxmen were also presented.		
	352690-29-39	352690-10-19	352690-19-39
	352690-20-59	352690-21-69	352690-22-79
	352690-23-89	352690-24-99	352690-25-09
	352690-26-19	352690-28-39	352690-29-49
	352690-30-79	352690-31-89	352690-32-99
	352690-33-09	352690-34-19	352690-36-39
	352690-39-69	352690-41-09	352690-43-29
	352690-45-49	352690-46-59	352690-48-79
	352690-49-89	352690-50-19	352690-51-29
	352690-53-49	352690-54-59	352690-55-69
	352690-56-79	352690-57-89	352690-58-99
	352690-59-09	352690-60-39	352690-61-49
	352690-62-59	352690-63-69	

RL: ~~8AC~~ (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and formulation of taxanes having improved solubility for  
 pharmaceutical use as antitumor agents)

RN 352427-29-3 CAPLUS  
 CN 2-Furanpropanoic acid,  $\beta$ -[[[1,1-dimethylpropoxy]carbonyl]amino]-  
 $\alpha$ -hydroxy-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-12b-(acetyloxy)-12-  
 (benzoyloxy)-2a,3,4,4A,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-  
 4a,8,13,13-tetramethyl-5-oxo-4-[[[phenylmethoxy]carbonyl]oxy]-7,11-methano-  
 h-m-cyclodec[4,3]benz[1,2-b]oxet-9-yl ester, (AR,BR)-(9CI)

**Absolute stereochemistry.**

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




```

RN      352698-18-1  CAPLIJS
CN      2-Thiophenepropenoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(1-
      methylthio)oxy]carbamoyl]amino-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-
      (acetyloxy)-12-(benzoyloxy)oxy]-2a,3,4,4a,5,6,6a,10,11,12,12a,12b-dodecahydro-
      6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-
      methano-1H-cycloodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,8R)-
      (9CI) (CA INDEX NAME)

```


**Absolute stereochemistry.**



RN 352698-19-2 CAPLUS  
CN 2-Thiophenepropionic acid,  $\alpha$ -hydroxy- $\beta$ -[[(1-methylethoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester. (nR,8R)- (9CI) (CA INDEX NAME)


### Absolute stereochemistry.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 352698-20-5 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-21-6 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\beta$ -(benzoylamino)- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 352698-24-9 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-25-0 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\beta$ -[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) INDEX NAME]

Absolute stereochemistry.



RN 352698-22-7 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\beta$ -[(2-furanylcarbonyl)amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-23-8 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\beta$ -[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-26-1 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\beta$ -[(2-furanylcarbonyl)amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-26-3 CAPLUS  
 CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(2-furanylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R,BR)- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-29-4 CAPLUS  
 CN 2-Thiophenepropanoic acid, α-hydroxy-β-[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 352698-30-7 CAPLUS  
 CN 2-Thiophenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-31-8 CAPLUS  
 CN 2-Thiophenepropanoic acid, α-hydroxy-β-[(2-thienylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 352698-32-9 CAPLUS  
 CN 3-Furanpropanoic acid, β-[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-33-0 CAPLUS  
 CN 2-Thiophenepropanoic acid, α-hydroxy-β-[(2-thienylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS) - (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 352698-34-1 CAPLUS  
 CN 3-Thiophenepropanoic acid, β-[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-36-3 CAPLUS  
 CN 3-Thiophenepropanoic acid, β-[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS) - (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-39-6 CAPLUS  
 CN 2-Puranpropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-], (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[[[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-41-0 CAPLUS

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 352698-45-4 CAPLUS  
 CN 2-Puranpropanoic acid, α-hydroxy-β-[[[(2-methylpropoxy)carbonyl]amino]-], (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[[[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-46-5 CAPLUS  
 CN 3-Thiophenepropanoic acid, α-hydroxy-β-[[[(2-methylpropoxy)carbonyl]amino]-], (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[[[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS) - (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 3-Puranpropanoic acid, α-hydroxy-β-[[[(2-methylpropoxy)carbonyl]amino]-], (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-

6,11-dihydroxy-4-[[[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-43-2 CAPLUS  
 CN 3-Puranpropanoic acid, α-hydroxy-β-[[[(2-methylpropoxy)carbonyl]amino]-], (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 352698-48-7 CAPLUS  
 CN 2-Puranpropanoic acid, α-hydroxy-β-[[[(2-methylpropoxy)carbonyl]amino]-], (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-49-8 CAPLUS  
 CN 2-Puranpropanoic acid, α-hydroxy-β-[[[(2R)-1-oxo-2-butenyl]amino]-], (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[[[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR) - (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 Absolute stereochemistry.  
 Double bond geometry as shown.




RN 352698-50-1 CAPLUS  
 CN 2-Thiophenepropanoic acid, α-hydroxy-β-(((2E)-1-oxo-2-butenyl)amino)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-((methoxycarbonyloxy)-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 352698-51-2 CAPLUS  
 CN 2-Puranpropanoic acid, α-hydroxy-β-((3-methyl-1-oxo-2-

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 352698-54-5 CAPLUS  
 CN 2-Puranpropanoic acid, β-(((1,1-dimethylethoxy)carbonyl)amino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(((phenylmethoxy)carbonyloxy)-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-55-6 CAPLUS  
 CN 2-Puranpropanoic acid, α-hydroxy-β-(((2E)-1-oxo-2-butenyl)amino)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-(((ethoxycarbonyloxy)-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-


4a,8,13,13-tetramethyl-5-oxo-4-(((phenylmethoxy)carbonyloxy)-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-53-4 CAPLUS  
 CN 2-Puranpropanoic acid, α-hydroxy-β-(((3-methyl-1-oxo-2-butenyl)amino)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-(((ethoxycarbonyloxy)-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-56-7 CAPLUS  
 CN 2-Thiophenepropanoic acid, α-hydroxy-β-(((2E)-1-oxo-2-butenyl)amino)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(((phenylmethoxy)carbonyloxy)-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 352698-57-8 CAPLUS  
 CN 2-Thiophenepropanoic acid, α-hydroxy-β-(((2E)-1-oxo-2-butenyl)amino)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-(((ethoxycarbonyloxy)-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.  
Double bond geometry as shown.


RN 352698-58-9 CAPLUS  
 CN 3-Puranpropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[ethoxycarbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-59-0 CAPLUS  
 CN 3-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[ethoxycarbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 352698-61-4 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[ethoxycarbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-62-5 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[ethoxycarbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (benzoyloxy)-4-[[ethoxycarbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


RN 352698-60-3 CAPLUS  
 CN 3-Puranpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[[ethoxycarbonyl]oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 352698-63-6 CAPLUS  
 CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[[ethoxycarbonyl]oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

IT 352427-31-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (Preparation and formulation of taxanes having improved solubility for pharmaceutical use as antitumor agents)  
 RN 352427-31-7 CAPLUS  
 CN 2-Puranpropanoic acid,  $\beta$ -[[[(1,1-dimethylpropoxy)carbonyl]amino]- $\alpha$ -hydroxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[ethoxycarbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-6-  
 [[methoxyacetyl]oxy]-4a,8,13,13-tetramethyl-5-oxo-4-  
 [[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-  
 b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:581700 CAPLUS  
 DOCUMENT NUMBER: 135:152982

TITLE: Preparation of C10 heterosubstituted acetate taxanes  
 as antitumor agents  
 INVENTOR(S): Holton, Robert A.  
 PATENT ASSIGNEE(S): Florida State University Research Foundation, Inc.,  
 USA

SOURCE: PCT Int. Appl., 56 pp.

CODEM: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGES: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056564	A1	20010809	WO 2001-US3553	20010202
M: AS, AL, AM, AT, AU, AZ, BA, BB, BJ, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368502	AA	20010809	CA 2001-2368502	20010202
AU 2001034792	AS	20010814	AU 2001-34792	20010202
AU 776767	B2	20040923		
BR 2001004350	A	20020102	BR 2001-4350	20010202
EP 1165068	A1	20020102	EP 2001-906951	20010202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002052403	A1	20020502	US 2001-776426	20010202
US 6638973	B2	20031028		
US 2002068755	A1	20020606	US 2001-775912	20010202
US 6664275	B2	20031216		
JP 2003521514	T2	20030715	JP 2001-556255	20010202
NZ 514406	A	20050128	NZ 2001-514406	20010202
ZA 2001006334	A	20020801	ZA 2001-6334	20010801
BR 2001006693	A	20041123	BR 2001-6693	20010808
NO 2001004756	A	20011129	NO 2001-4756	20011001
ZA 2001008052	A	20031201	ZA 2001-8052	20011001
US 2004024051	A1	20040205	US 2003-609301	20030627
US 6872837	B2	20050329		
US 2004097579	A1	20040520	US 2003-680649	20031007
US 2005143447	A1	20050630	US 2005-68166	20050228
PRIORITY APPLN. INFO.:				
			US 2000-179669P	P 20000202
			US 2000-179670P	P 20000202
			US 2000-179671P	P 20000202
			US 2000-179672P	P 20000202

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 2000-179684P P 20000202  
 US 2000-179782P P 20000202  
 US 2000-179793P P 20000202  
 US 2000-179794P P 20000202  
 US 2001-775912 A1 20010202  
 US 2001-776426 A3 20010202  
 WO 2001-US3553 W 20010202  
 US 2003-609301 A1 20030627

OTHER SOURCE(S):  
 GI

MARPAT 135:152982



AB Taxanes of formula I [R1 = H, OH; R2 = acyloxy; R3 = keto, OH, acyloxy;  
 R4 = heterosubstituted acetate; X1 = alkyl, alkenyl, Ph, heterocyclyl; X2 =  
 acyl, CO2alkyl, CO2heterocyclyl, etc.], having a heterosubstituted  
 acetate substituent at C(10), are prepared as antitumor agents. Thus, II was  
 prepared and had in vitro cytotoxicity of ID50 < 1 nm against HCT116 cells.


IT 352427-29-3P 352427-31-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of C10 heterosubstituted acetate taxanes as antitumor  
 agents)

RN 352427-29-3 CAPLUS  
 CN 2-Puranpropanoic acid, β-[[[(1,1-dimethylpropoxy)carbonyl]amino]-

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-  
 (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-  
 4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-  
 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 352427-31-7 CAPLUS

CN 2-Puranpropanoic acid, β-[[[(1,1-dimethylpropoxy)carbonyl]amino]-  
 α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-  
 (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-6-  
 [[methoxyacetyl]oxy]-4a,8,13,13-tetramethyl-5-oxo-4-  
 [[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-  
 b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1994-701105 CAPLUS  
 DOCUMENT NUMBER: 121:301105  
 TITLE: Preparation of taxane derivatives as antiproliferatives  
 INVENTOR(S): Bouchard, Herve; Bourzat, Jean-Dominique; commercon, Alain  
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer SA, Fr.  
 SOURCE: Fr. Demande, 44 pp.  
 CODEN: FREEHL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2698363	A1	19940527	FR 1992-14023	19921123
FR 2698363	B1	19941230		
CA 2149758	AA	19940609	CA 1993-2149758	19931122
WO 9412484	A1	19940609	WO 1993-FR1145	19931122
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, US				
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9455659	A1	19940622	AU 1994-55659	19931122
AU 680455	B2	19970731		
ZA 9308728	A	19940628	ZA 1993-8728	19931122
EP 665916	A1	19950906	EP 1994-900862	19931122
EP 665916	B1	19970122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08503486	T2	19960416	JP 1993-512841	19931122
HU 74069	A2	19961028	HU 1995-1500	19931122
AT 148111	E	19970215	AT 1994-900862	19931122
ES 2096440	T3	19970301	ES 1994-900862	19931122
NO 9502017	A	19950522	NO 1995-2017	19950522
FI 9502482	A	19950524	FI 1995-2482	19950522
US 5606083	A	19970225	US 1995-424512	19950523
PRIORITY APPL. INFO.:			FR 1992-14023	A
			WO 1993-FR1145	W
				19931122

OTHER SOURCE(S): MARPAT 121:301105  
 GI

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB Title compds. [I; R = H or Ac; R1 = Bz, CO2R2; R2 = (cyclo)alk(enyl), Ph, heterocyclyl, etc.; R3 = 5-membered heteroaryl] were prepared as antiproliferatives (no data). Thus, (2R,4S,5R)-3-tert-butoxycarbonyl-2-(4-methoxyphenyl)-4-(3-thienyl)oxazolidine-5-carboxylic acid (6-step preparation given) was esterified by 4-acetoxy-2a-benzoyloxy-5β,20-epoxy-1,13a-dihydroxy-9-oxo-7β,10β-bis(2,2,2-trichloroethoxycarbonyloxy)-11-taxene to give, in 3 addnl. steps, 4-acetoxy-2a-benzoyloxy-5β,20-epoxy-1,7β,10β-trihydroxy-9-oxo-11-taxen-13a-yl (2R,3S)-3-tert-butoxycarbonylamino-3-(3-thienyl)-2-hydroxypropionate.

IT 159180-02-6P 159180-03-7P 159180-11-7P  
 159180-12-8P 159180-20-8P 159180-21-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in preparation of antiproliferative)

RN 159180-02-6 CAPLUS  
 CN 3-Thiophenepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4,6-bis[[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, [2aR-[2aα,4β,4aβ,6β,9α(αR\*,βS\*),11α,12a,12aα,12bα]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 159180-03-7 CAPLUS  
 CN 3-Thiophenepropanoic acid, β-amino-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4,6-bis[[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, [2aR-[2aα,4β,4aβ,6β,9α(αR\*,βS\*),11α,12a,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159180-11-7 CAPLUS  
 CN 2-Thiophenepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4,6-bis[[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] ester, [2aR-[2aα,4β,4aβ,6β,9α(αR\*,βS\*),11α,12a,12aα,12bα]]- (9CI) (CA INDEX NAME)

LJ ANSWER 4 OF 4 CAPIUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.



RN 159180-12-8 CAPIUS  
CN 2-Thiophenepropanoic acid, β-amino-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4,6-bis[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR\*,βS\*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159180-20-8 CAPIUS  
CN 3-Puranpropanoic acid, β-[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-

LJ ANSWER 4 OF 4 CAPIUS COPYRIGHT 2005 ACS on STN (Continued)

LJ ANSWER 4 OF 4 CAPIUS COPYRIGHT 2005 ACS on STN (Continued)  
tetramethyl-5-oxo-4,6-bis[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR\*,βS\*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159180-21-9 CAPIUS  
CN 3-Puranpropanoic acid, β-amino-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4,6-bis[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR\*,βS\*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

